Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
- Published on 01/09/2025
- Reading time: 4 min.
Liu Jiaxuan 1, Zhang Jiayang 2, Li Huiping 2, Song Guohong 2, Di Lijun 2, Jiang Hanfang 2, Yan Ying 2, Wang Huan 2, Wang Jing 2, Liu Xiaoran 2, Shao Bin 2, Li Qiao 1
1 https://ror.org/02drdmm93 Department of Medical Oncology National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College No.17 PanjiayuanNanli, Chaoyang District 100021 Beijing China
2 https://ror.org/00nyxxr91 Department of Breast Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital & Institute No.52 Fucheng Road, Haidian District 100142 Beijing China
Abstract
Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluate the efficacy and safety of anlotinib plus MCT for HER2 negative MBC. Patients with HER2 negative MBC who received metronomic chemotherapy (Vinorelbine (NVB), Capecitabine (CAPE), Etoposide...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology